## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($52.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Barchart.com | 20251216T124258 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne Corporation (TECH), a mid-cap life sciences company, has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date and over the past 52 weeks, despite a recent three-month gain. The company's Q1 2026 revenue declined due to headwinds in cell therapy timing and biotech funding softness. Despite its recent struggles, analysts maintain a "Strong Buy" rating for TECH with a significant upside to its mean price target.

**2. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Palmetto Grain Brokerage | 20251216T120846 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne Corporation (TECH) has seen its shares decrease by nearly 26% from its 52-week high, lagging behind the Health Care Select Sector SPDR Fund (XLV) over the past three months and year-to-date. The company reported a 1% year-over-year revenue decline in Q1 2026, pressured by cell therapy timing headwinds and biotech funding softness. Despite its underperformance compared to rivals like Quest Diagnostics Incorporated (DGX), analysts maintain a "Strong Buy" rating with a significant price target premium.

**3. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251216T074000 | Somewhat-Bearish | Relevance: 98%
- Bio-Techne Corporation (TECH) has shown underperformance compared to the broader healthcare sector (XLV), with its stock decreasing almost 26% from its 52-week high. While it gained 13.7% in the past three months, it lagged XLV's 14% gain. The company's recent Q1 2026 revenue decline due to cell therapy timing and biotech funding softness contributed to investor concerns, despite analysts maintaining a "Strong Buy" rating.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Near-term weakness: 6.7% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 26.2x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.9B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 26.2 |
| Current P/E | 28.9 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-1.0% over 5 days). Below STRENGTH zone by 9.0pp (needs >4.0% for momentum thesis). AM_20 at -6.9% indicates price below own 20MA trend. Underperforming sector by 6.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.66), momentum weakening. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.02% (CS: 9) | Weak |
| RSI_14 | 38.1 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 0.931x | Below |
| vs SMA50 | 0.933x | Below |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $56.99
- **Stop Loss:** $52.71 (7.5% risk)
- **Target:** $65.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 252
- **Position Value:** $14,361.48
- **Portfolio %:** 14.36%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*